Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Background It has been suggested that clopidogrel may be less effective in reducing the rate
of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Background—Both clopidogrel and prasugrel require biotransformation to active metabolites
by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of …

Clopidogrel has become the mainstay oral antiplatelet regimen to prevent recurrent
ischemic events after acute coronary syndromes or stent placement. However, there is …

A double‐blind crossover study was conducted in four CYP2C19 genotype–defined
metabolizer groups to assess whether increase in clopidogrel dosing can overcome …

Background Previous studies have investigated the relationship between CYP2C19
polymorphism and clinical prognosis in coronary artery disease patients treated with …

Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Background: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A
(CYP3A) isoenzymes, including CYP3A5, in order to be active. It is controversial whether …